💨 Abstract

The article discusses the recent launch of Mounjaro, an anti-obesity drug in India, which contains the active pharmaceutical ingredient tirzepatide. Despite being priced lower compared to developed countries, its high cost (nearly Rs 2 lakh annually per patient) means it is out of reach for most Indians.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖